Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Medco Research Inc. shareholders who opposed the terms of the proposed merger with Repligen Corp. got their wish, with the deal foundering last week after the companies couldn't reach a new deal.
The issue now is whether MRE shareholders have traded
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury